Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 8/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.31 |
| ▸ | ABL2 | P42684 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.31 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 2/20 | 0.31 |
| ▸ | BRAF | P15056 | 2/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514304 | 0.75 | NOS1 (0.47) | HTTPTK2TGFBR1CYP3A4CYP2C8 | |
| SCHEMBL19152664 | 0.75 | HTT (0.45) | HTTPTK2TGFBR1CYP3A4CYP2C8 | |
| SCHEMBL2596969 | 0.75 | NCF1 (0.41) | HTTPTK2TGFBR1CYP3A4CYP2C8 | |
| SCHEMBL2598373 | 0.75 | MAPKAPK2 (0.38) | HTTPTK2TGFBR1CYP3A4CYP2C8 | |
| SCHEMBL3465347 | 0.75 | NOS1 (0.47) | HTTPTK2TGFBR1CYP3A4CYP2C8 | |
| SCHEMBL2598398 | 0.75 | NOS1 (0.47) | HTTPTK2TGFBR1CYP3A4CYP2C8 | |
| SCHEMBL29951183 | 0.75 | HTT (0.41) | HTTPTK2TGFBR1CYP3A4CYP2C8 | |
| SCHEMBL9073237 | 0.74 | MAPT (0.38) | HTTPTK2CYP3A4CSNK1A1NOS1 | |
| SCHEMBL23629251 | 0.73 | KDM5A (0.50) | — | |
| SCHEMBL23629273 | 0.72 | BTK (0.54) | PTK2CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371430-B2 | 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives | MERCK PATENT GMBH (DE) | 2025-07-29 | — | — | US | claimed |
| CN-116375701-A | Bicyclic heterocyclic compounds, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-3846904-A1 | 5-MORPHOLIN-4-YL-PYRAZOLO[4,3-B]PYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2021-07-14 | — | — | EP | disclosed |
| US-7652035-B2 | CRF receptor antagonists and methods relating thereto | Neurocrine Bioscience, Inc. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1802621-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | SMITHKLINE BEECHAM CORK LTD (IE) | 2009-05-06 | — | — | EP | disclosed |
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2008-03-13 | — | — | US | disclosed |
| EP-1802621-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | SB Pharmco Puerto Rico Inc. (PR) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044821-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | SB PHARMCO PUERTO RICO INC. (PR) | 2006-04-27 | — | — | WO | disclosed |
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-03-11 | — | — | US | disclosed |
| WO-2003076408-A2 | INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | GUCY1B1, GUCY1A1, GUCY1A2 | HTT 4614/4885PTK2 3430/4885TGFBR1 1076/4885 |
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | CRHR1, CRHR2, SCTR | HTT 946/4885PTK2 4477/4885TGFBR1 3601/4885 |
| US-12371430-B2 | 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives | ATR, CDK1, CDKN1A | HTT 3076/4885PTK2 1409/4885TGFBR1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.